new peptide retatrutide GLP-3 R 15mg Retatrutide Peptide Weight Loss Therapy

Weight loss can make parts of your body look different

Retatrutide is an unlicensed investigational peptide in the UK with no MHRA or EMA marketing authorisation as of 2024

Exenatide, the active ingredient in Bydureon BCise, was the first GLP-1 medication to be approved by the FDA

Readers should verify the current authorisation status via the MHRA and EMA medicines databases, as the regulatory position may change as Phase 3 data mature

So your prescriber will work with you to find the closest equivalent

New indications expand use cases Perhaps just as important as the wave of new GLP-1/GIP drugs for obesity is the expansion of already approved GLP-1 drugs into other therapeutic areas